Epalinges, Vaud, Switzerland
Driving strategic clinical evidence generation and leading Medical Affairs execution: Cultivating collaborative partnerships with key opinion leaders and stakeholders to secure regulatory approvals and accelerate market expansion.
•Responsible for Dexter’s global Medical Affairs strategy, ensuring alignment with clinical and economic evidence generation needs • Partner with Commercial and Market Access teams to identify strategic centers and accelerating platform adoption
• Established the Global Medical Affairs function from the ground up, defining the operating model, SOPs, governance frameworks and global budgets • Directed comprehensive real-world evidence and publication strategies, driving the production of 20 peer-reviewed publications and over 65 scientific abstracts in three years to demonstrate product value and differentiation • Elevated the visibility of the DEXTER® Robotic Surgery System within the scientific community, establishing credibility and trust.
• Translated regional medical strategy into aligned Medical Excellence priorities, ensuring adherence to governance frameworks • Oversaw complex budget allocations to achieve cost savings and enhance productivity • Partnered with teams across EMEA, US, and APAC to harmonize global governance of medical affairs strategies and execution
• Utilized Lean Six Sigma methodologies to streamline IIT and IME processes, optimizing CRM tracking tool and processes to ensure strict alignment with the MedTech code while improving resource allocation and KPI monitoring • Tripled scientific visibility and share of voice at major international congresses through targeted KOL partnerships, publication planning, and scientific societies engagement
• Established and chaired EMEA investigator-initiated research board, managing a strategic portfolio of over 30 international studies. Led the grant management system transformation • Served as a subject matter expert in Diabetes, supporting Regulatory affairs in completing Clinical Evaluation Report aligned with the MDR requirements • Managed Promomaterial review process and Advisory Boards.
• Managed Phase II - IV studies for subcutaneous glucose sensor and Insulin pump products. Generated clinical & health economic evidences securing reimbursement across 5 major European markets • Led cross-functional clinical study teams, hired and developed new team members, managed budgets, and project timelines. • Collaborated with marketing on launch readiness. Reviewed clinical data, provided expert analysis, and contributed to study reports and publications.
Directed the multinational, multi-center INTERPRET post-market study across 15 countries (30 clinical sites) and designed complex Phase II/III studies of investigational products
Start-up portfolio (Phase I schizophrenia; Phase II traumatic brain injury). Supported fundraising, investors relations, and regular presentations to the Board. Responsible for portfolio assessment of early-stage neuroscience programs, including pre-launch market mapping and competitors.